Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 8/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.73 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.73 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.73 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.73 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.73 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.73 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.73 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.73 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.73 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22364346 | 1.00 | CHRM3 (0.73) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| SCHEMBL25126204 | 0.92 | CHRM3 (0.75) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1566144 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1566459 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1736633 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL13298567 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1478523 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL12046704 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL1735698 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F | |
| Solifenacin SCHEMBL9971260 | 0.84 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KCNH2CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20110077405-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE (S)-1-PHENYI-1,2,3,4- TETRAHYDROISOQUINOLINE | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2011-03-31 | — | — | US | disclosed |
| US-20110077405-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE (S)-1-PHENYI-1,2,3,4- TETRAHYDROISOQUINOLINE | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | CHERP, ORAI1, CA2 | CHRM3 3701/4885CHRM2 3160/4885CHRM1 2928/4885 |
| US-20110077405-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE (S)-1-PHENYI-1,2,3,4- TETRAHYDROISOQUINOLINE | HTR1D, CHRM1, HTR1A | CHRM3 31/4885CHRM2 35/4885CHRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.